Article Information
History
- May 3, 2022.
Article Versions
- Version 1 (April 29, 2022 - 16:24).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Sara Carazo, MD PhD1,*,
- Danuta M. Skowronski, MD FRCPC2,
- Marc Brisson, PhD3,4,
- Chantal Sauvageau, MD1,3,4,
- Nicholas Brousseau, MD MSc1,3,4,
- Rodica Gilca, MD PhD1,3,4,
- Manale Ouakki, MSc1,
- Sapha Barkati, MD5,
- Judith Fafard, MD6,
- Denis Talbot, PhD3,4,
- Vladimir Gilca, MD1,
- Geneviève Deceuninck, MD3,
- Christophe Garenc, PhD1,3,
- Alex Carignan, MD7,
- Philippe De Wals, MD PhD1,3,4 and
- Gaston De Serres, MD PhD1,3,4
- 1Biological and occupational risks unit. Institut national de santé publique du Québec, Quebec City, Quebec, Canada
- 2Communicable Diseases and Immunization Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada
- 3Centre Hospitalier Universitaire (CHU) de Québec–Université Laval Research Center, Quebec City, Quebec, Canada
- 4Social and preventive medicine department, Faculty of medicine, Laval University, Quebec city, Quebec, Canada
- 5Department of Medicine, Division of infectious diseases, McGill University Health Center, McGill University, Montreal, Quebec, Canada
- 6Laboratoire de Santé Publique du Québec, Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, Quebec, Canada
- 7Department of microbiology and infectious diseases, Sherbrook University, Sherbrook, Quebec, Canada
- ↵*Corresponding author:
Sara Carazo, Institut national de santé publique du Québec, 2400, Avenue d’Estimauville, Québec, Québec, G1E 7G9, Canada, +1 418 666 7000 ext. 10020, sara.carazo{at}inspq.qc.ca
Posted May 03, 2022.
Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination
